Georgia Life Sciences Joins National Coalition Urging Congressional Action on Key Innovation Policies

Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay:

 

1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program

The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on.

 

2. Extend the SBIR/STTR Programs

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline,

 

3. Advance PBM Transparency Reforms

Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system.

 

A Unified Message from the Life Sciences Community

The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message—these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress.

 

Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.


Read the full CSBA letter here
March 24, 2026
Georgia Life Sciences is thrilled to be featured in the very first Atlanta edition of Inside Medicine . This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. Also in the issue, GLS's Kennedy Dumas is featured, sharing her journey on how observation and research evolved into a powerful practice of journaling. As the founder of Stationery Black, she creates notebooks designed to showcase, uplift, and inspire people of color. Read the full article here.
March 24, 2026
B y Trevor Williams , March 24, 2026 | Global Atlanta More than 60 Belgian firms have found a home in Georgia, but nothing on this scale has yet been seen in the state. The amalgam of Belgian investment, carried out over a half-century, translates to about 5,000 current jobs. Gwinnett offered $174 million in incentives to win the project, including property tax abatements, fee waivers and utility improvements, according to Rowen. UCB is set to bring in artificial intelligence, advanced robotics and automation at the site. Biologics are therapies made from living organisms, promising cutting-edge research and manufacturing. Maria Thacker Goethe , president and CEO of Georgia Life Sciences , said the move gives state leaders even more impetus to work collaboratively to build Georgia’s talent pipeline “across every stage — from high school exposure and technical credentials to community college, university, and incumbent-worker upskilling.” “UCB’s decision underscores the strength of Georgia’s talent base, manufacturing capacity, and collaborative business climate, and it reflects the kind of long-term investment that helps build a more resilient U.S. biomanufacturing footprint,” Ms. Goethe told Global Atlanta in an email. Nine of the 16 FDA approvals for UCB drugs and therapies have come within the last three years, showing its prioritization of the U.S. market, where headcount has grown 73 percent since 2017 to 2,000 people. UCB’s products treat severe neurological and immunological conditions like epilepsy, lupus, Parkinson’s disease, rheumatoid arthritis and many more. Read the full article here: UCB Sticks With Georgia, Placing $2 Billion Bet on State’s Life Sciences Ecosystem - Global Atlanta
March 17, 2026
Georgia Life Sciences leads effort to establish bipartisan caucus focused on advancing the state’s growing life sciences economy
MORE POSTS